NCT06314997 (Liquid-DRER2) is a Phase 2 clinical trial of panitumumab (EGFR inhibitors) in Recurrence Free Survival, sponsored by Matteo's Friends.

Who is sponsoring NCT06314997?

NCT06314997 is sponsored by Matteo's Friends.

What drugs are being tested in NCT06314997?

Interventions in NCT06314997: panitumumab (EGFR inhibitors).

What condition does NCT06314997 study?

NCT06314997 studies Recurrence Free Survival.

Is NCT06314997 still recruiting?

NCT06314997 is currently recruiting now. Last updated 18 March 2024.

Last reviewed 2024-03-18 · How we verify

NCT06314997: Liquid-DRER2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dynamic Changes in Circulating Tumour Cells Protein Expression

Recruiting now Phase 2 Last updated 18 March 2024

What this trial tests

Phase 2 trial testing panitumumab (EGFR inhibitors) in Recurrence Free Survival in 150 participants. Currently enrolling.

Timeline

14 January 2019

Primary endpoint
17 December 2024

18 December 2027

Quick facts

Lead sponsor	Matteo's Friends
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	150
Start date	14 January 2019
Primary completion	17 December 2024
Estimated completion	18 December 2027
Sites	1 location across Italy

Drugs / interventions tested

panitumumab (EGFR inhibitors) — full drug profile →

Conditions studied

Recurrence Free Survival — all drugs for Recurrence Free Survival →

Sponsor

Matteo's Friends — full company profile →

Who can join

Adults 18 to 100, any sex, with Recurrence Free Survival. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This multicenter study, randomized, controlled of blood-based biomarker-driven targhet therapy. Patients were selectedm( at Hospital San Giovanni and Celio in Rome) according to CTCs results ( CTCs-guided managment performed at University Magna Graecia) or managed by the treating clinician according to standard pathological criteria (standard management). The participants were assigned to trial groups with the use of block randomization stratified according to the enrolling center location metropolitan) and tumor stage (T3 or T4).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Recurrence Free Survival

Currently open trials in the same condition.

NCT07391137 — CRUCIAL-R Study : Cruciferous Vegetables Dietary Regimen in NMIBC · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06314997 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Matteo's Friends
Last refreshed: 18 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06314997.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing